Xemocid5%

Xemocid is a parenteral (intravenous) nutrition solution used to supply amino acids, fluid, calories (via D-Sorbitol), and electrolytes to patients who cannot meet their nutritional requirements through oral or enteral feeding.

Established/Guideline-Supported Uses

• Source of amino acids for protein synthesis in patients requiring total or partial parenteral nutrition, including peri-operative and post-operative patients unable to tolerate oral/enteral intake.
• Nutritional support in catabolic states such as major surgery, trauma, sepsis, burns, and prolonged critical illness, where protein and calorie requirements are increased.
• Nutritional support in patients with gastrointestinal dysfunction (e.g., short bowel syndrome, severe malabsorption, prolonged ileus, inflammatory bowel disease flares) preventing adequate enteral intake.
• Adjunctive nutritional support in patients with cancer, chronic renal insufficiency, or hepatic insufficiency who have inadequate protein/calorie intake, used alongside disease-specific management, under close specialist supervision.

Use Requiring Combination Therapy

Xemocid is typically administered as part of a complete parenteral nutrition regimen that also includes an energy source (dextrose and/or lipid emulsion), vitamins, and trace elements, prescribed and adjusted by the treating physician/nutrition team based on individual metabolic needs.

Amino Acid + D-Sorbitol + Electrolytes is a sterile intravenous infusion solution (commonly supplied as a 5% or 10% concentration in 500 mL, with some 100 mL presentations) containing a balanced mixture of essential and non-essential amino acids, D-Sorbitol as a carbohydrate energy source, and electrolytes.

Typical Composition (per 100 mL of 5% solution)

Total nitrogen content is approximately 7.25 g/L, providing approximately 371 Kcal/L of energy. Exact composition may vary slightly between brands; always check the specific product label.

Xemocid is a ready-to-use sterile intravenous infusion combining essential and non-essential amino acids with D-Sorbitol (a carbohydrate that provides energy independent of insulin in the short term) and physiologic electrolytes (sodium, potassium, magnesium, chloride, acetate).

It is used as part of parenteral nutrition support to supply the nitrogen (protein) building blocks the body needs for tissue repair, wound healing, and maintenance of lean body mass, together with fluid and electrolyte replacement, in patients who cannot obtain adequate nutrition by mouth or via the gut.

Xemocid is a prescription-only product administered by intravenous infusion under the supervision of a physician or trained healthcare professional, typically in a hospital or clinical infusion setting.

Parenteral Nutrition Solution - IV Amino Acid, Carbohydrate (D-Sorbitol) and Electrolyte Combination. Xemocid belongs to the class of intravenous nutritional/electrolyte replacement solutions used in total or supplemental parenteral nutrition.

Amino Acid + D-Sorbitol + Electrolytes supplies a balanced pattern of essential and non-essential amino acids that are utilized by the body for protein synthesis, supporting nitrogen balance, tissue repair, and wound healing in patients unable to meet protein needs orally or enterally.

D-Sorbitol, a hexahydric sugar alcohol, is metabolized primarily in the liver (largely via the sorbitol dehydrogenase and fructokinase/fructose pathway) to provide a source of calories with a relatively insulin-independent initial uptake, complementing the amino acid component. The accompanying electrolytes (sodium, potassium, magnesium, chloride, acetate) help maintain fluid and electrolyte balance during infusion; acetate is metabolized to bicarbonate, contributing to acid-base buffering.

At recommended infusion rates, the amino acid component itself has no significant pharmacodynamic (drug-like) activity beyond its role as a nutritional substrate.

Xemocid is for intravenous infusion only, administered by or under the direct supervision of a physician or trained healthcare professional in a hospital or clinical infusion setting - it is not intended for self-administration.

• Administer via a controlled intravenous infusion (peripheral or central line, depending on osmolarity and concentration of the specific product), using an infusion pump or rate-controlled set to avoid too-rapid administration.
• Do not give as a rapid peripheral bolus/push injection; the infusion rate must be controlled and increased gradually to reduce the risk of hyperglycemia, osmotic effects, and electrolyte shifts.
• Inspect the solution visually before use; do not use if the container is damaged, the solution is cloudy, discolored, or contains particulate matter.
• Use aseptic technique throughout preparation and administration; discard any unused portion of an opened container - do not use as a multi-dose container.
• Administer as part of a complete, individualized parenteral nutrition regimen, with regular clinical and laboratory monitoring (fluid balance, electrolytes, blood glucose, renal and liver function).

At recommended infusion rates and doses, Xemocid has no significant pharmacological activity of its own and is not expected to interact with other medicines in the way a typical drug does. However, the following points are clinically relevant when it is co-administered with other therapies:

• Insulin and other glucose-lowering agents: Because D-Sorbitol is metabolized to provide calories and can raise blood glucose, dose adjustment of insulin or oral hypoglycemic agents may be needed, especially in patients with diabetes mellitus or glucose intolerance.
• Potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers: Co-administration with the potassium content of Xemocid may increase the risk of hyperkalemia; serum potassium should be monitored.
• Other intravenous fluids/medications given via the same line: Physical/chemical incompatibility is possible; Xemocid should not be mixed with other drugs or infusates in the same container or line unless compatibility has been confirmed.

Most adverse effects of Xemocid are related to infusion rate or the underlying clinical condition rather than the amino acid content itself.

• Common: Nausea (uncommon at recommended rates, more frequent with rapid infusion), warmth/flushing, sweating.
• With rapid or excessive infusion: Vomiting, headache, chills, hyperglycemia, osmotic diuresis.
• Infusion-site reactions: Pain, phlebitis, or thrombophlebitis, particularly with peripheral vein administration or hypertonic concentrations.
• Metabolic/laboratory changes: Transient elevation of liver enzymes, electrolyte disturbances (hyperkalemia, hypophosphatemia), and hyperglycemia - see also Precautions and Warnings.
• Rare: Hypersensitivity reactions (rash, fever); hyperphenylalaninemia in preterm infants receiving prolonged therapy.

Report any signs of an allergic reaction, breathing difficulty, chest pain, or infusion-site swelling/pain to the healthcare team immediately.

Xemocid should be used during pregnancy only if clearly needed, when the potential nutritional benefit to the mother justifies the potential risk, and under close physician supervision - formal controlled studies in pregnant women are limited, although amino acid parenteral nutrition solutions have been used in pregnancy when clinically indicated (e.g., severe hyperemesis or malnutrition). A physician should be consulted before use in pregnancy.

Similarly, use during breastfeeding should be under medical supervision; a physician should weigh the mother's nutritional needs against any theoretical risk and advise on breastfeeding during parenteral nutrition. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

Xemocid should be used with caution and close monitoring in the following situations:

• Diabetes mellitus/glucose intolerance: D-Sorbitol can raise blood glucose; monitor blood glucose closely and adjust insulin/glucose-lowering therapy as needed.
• Cardiac or renal impairment: Risk of fluid overload, electrolyte imbalance, and pulmonary edema with large-volume infusions; use reduced volumes and closer monitoring in heart failure or renal insufficiency.
• Hepatic impairment: Monitor liver function and ammonia levels; adjust amino acid load as needed - see also Contraindications for severe hepatic failure.
• Electrolyte disturbances: Regularly monitor serum sodium, potassium, magnesium, and phosphate, particularly with rapid or prolonged infusions; correct pre-existing imbalances before starting therapy.
• Infusion rate/route: Not for rapid peripheral bolus administration; infusion rate must be controlled and increased gradually - see Administration.
• Prolonged parenteral nutrition: Monitor trace elements (copper, zinc) and consider thiamine supplementation in severely malnourished patients to reduce the risk of refeeding syndrome.
• Preterm infants: Monitor phenylalanine levels due to risk of hyperphenylalaninemia with prolonged use.

Overdose or excessively rapid infusion of Xemocid can cause nausea, vomiting, sweating, flushing, thrombophlebitis, osmotic diuresis with dehydration, electrolyte disturbances, and hyperglycemia. In severe cases, fluid overload, pulmonary edema, or metabolic acidosis may occur.

If signs of overdose or an adverse reaction occur, the infusion should be slowed or stopped immediately and the patient assessed by the healthcare team; supportive treatment should be given as clinically indicated. Because this product is administered under direct medical supervision, any suspected overdose should be managed immediately by the attending healthcare professional; if this occurs outside a monitored setting, seek immediate medical attention or contact emergency services.

Store between 15°C and 25°C, protected from light. Do not freeze. Keep out of reach of children. Use immediately after opening/puncturing the container and discard any unused portion; do not use if the seal is broken, the solution is cloudy or discolored, or particulate matter is visible.

Renal impairment: Use with caution; nitrogen load and infusion volume require individualization, and Xemocid is contraindicated in severe uremia without access to dialysis - see Contraindications.

Hepatic impairment: Use with caution and monitor liver function/ammonia; contraindicated in severe hepatic failure or hepatic coma - see Contraindications.

Elderly patients: No specific dose adjustment is established, but elderly patients may have reduced cardiac, renal, or hepatic reserve; use conservative infusion volumes/rates and monitor fluid and electrolyte status closely.

Diabetic patients: Monitor blood glucose closely because of the D-Sorbitol content; adjust glucose-lowering therapy as needed.

Hereditary fructose intolerance: Xemocid must not be used - see Contraindications.

The duration of treatment with Xemocid is determined by the treating physician based on the underlying clinical condition and the time needed until adequate oral or enteral nutrition can be resumed. It may range from a few days (e.g., peri-operative support) to several weeks in patients with prolonged gastrointestinal dysfunction or critical illness. Nutritional status, fluid balance, and laboratory parameters should be reassessed regularly, and parenteral nutrition should be discontinued or tapered as soon as adequate oral/enteral intake is achievable.

Amino Acid + D-Sorbitol + Electrolytes belongs to the parenteral nutrition / intravenous amino acid-carbohydrate-electrolyte combination solution class, used for nutritional support and fluid/electrolyte replacement in patients unable to meet requirements orally or enterally.

Amino Acid + D-Sorbitol + Electrolytes acts by directly supplying the essential and non-essential amino acid building blocks required for endogenous protein synthesis, helping to maintain nitrogen balance and support tissue repair. D-Sorbitol provides a supplementary carbohydrate energy source that is metabolized primarily in the liver, sparing amino acids from being used for energy so they can be directed toward protein synthesis instead. The accompanying electrolytes (sodium, potassium, magnesium, chloride, acetate) replace ongoing losses and help maintain physiological fluid and acid-base balance during intravenous nutrition support.

Xemocid may be used in children and infants, including preterm neonates, who require parenteral nutrition support and cannot meet protein/calorie requirements orally or enterally, under the direct supervision of a pediatrician or neonatologist experienced in parenteral nutrition.

Dosing is individualized and typically started at a low infusion rate with gradual increase based on tolerance, with reported doses around 28-35 mL/kg/day of the 5% solution in published clinical use; exact requirements depend on the child's age, weight, and metabolic status. Formal pediatric labeling for optimal dosing across all age groups is limited, and safety and efficacy in extremely low birth weight or critically ill neonates should be assessed individually by the treating specialist, with close monitoring of blood glucose, electrolytes, and phenylalanine levels (preterm infants are at risk of hyperphenylalaninemia with prolonged use).